07:00 , Apr 27, 2009 |  BC Week In Review  |  Clinical News

Ariad preclinical data

In a mouse xenograft model of anaplastic large cell lymphoma (ALCL), daily oral administration of ALK inhibitor elicited a dose-dependent antitumor effect, with near-complete tumor regression observed at the highest doses of 50 and 100...
07:00 , Oct 2, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Insulin receptor tyrosine kinase (INSR tyrosine kinase) In vitro and in vivo studies suggest that a class of...
07:00 , Aug 25, 2008 |  BC Week In Review  |  Company News

RecepterBio Inc., Telik deal

ReceptorBio received exclusive rights from Telik to develop and commercialize Telik’s small molecule insulin receptor activators in the U.S., Europe and other undisclosed countries. The undisclosed molecules are in preclinical testing to treat Type II...
07:00 , May 10, 1999 |  BC Week In Review  |  Clinical News

Merck Research Laboratories preclinical data

Merck researchers published in Science the identification of a small molecule, L-783,281, that selectively activates the insulin receptor tyrosine kinase and acts as an insulin mimetic in vitro. In two mouse models of diabetes (lacking...